FULC Fulcrum Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1680581 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,752.0%
TTM net income YoY90.0%
TTM EPS YoY89.9%
Revenue 3-yr CAGR61.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-27.4%
Net margin-12.2%
FCF margin-3.1%
EBITDA margin-25.3%
Returns
ROE-4.1%
ROA-3.8%
ROIC (approx.)-8.8%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets6.8%
Debt / equity0.00x
Current ratio22.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.23x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | — | $0 |
| R&D expense | $3.03M | $12.44M | $14.08M | $15.42M | $14.30M | $12.99M | $13.40M | $11.71M |
| SG&A expense | $8.44M | $7.46M | $8.10M | $7.28M | $7.56M | $6.83M | $7.00M | $7.72M |
| Operating income | -$13.86M | -$29.31M | -$22.19M | -$22.69M | -$21.86M | -$19.82M | -$20.40M | -$19.43M |
| Net income | -$10.94M | -$26.18M | -$18.89M | -$20.33M | -$19.59M | -$17.30M | -$17.66M | -$16.57M |
| EBITDA | -$13.56M | -$29.11M | -$21.85M | -$22.35M | -$21.56M | -$19.52M | -$20.05M | -$19.06M |
| EPS (basic) | -0.14 | -0.34 | -0.25 | — | -0.31 | -0.28 | -0.28 | — |
| EPS (diluted) | -0.14 | -0.34 | -0.25 | — | -0.31 | -0.28 | -0.28 | — |
| Weighted avg. shares (diluted) | 76.32M | 76.26M | 76.22M | — | 62.60M | 62.54M | 62.48M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $116.41M | $48.47M | $50.26M | $197.53M | $47.08M | $42.59M | $42.18M | $58.21M |
| Current assets | $310.80M | $322.85M | $338.67M | $357.48M | $205.86M | $219.37M | $232.56M | $249.92M |
| PP&E, net | $0 | $0 | $2.49M | $2.82M | $3.17M | $3.27M | $3.55M | $3.90M |
| Total assets | $310.81M | $323.95M | $346.77M | $366.28M | $214.86M | $228.84M | $242.65M | $260.72M |
| Current liabilities | $8.59M | $10.30M | $9.86M | $13.05M | $11.63M | $8.98M | $8.10M | $11.04M |
| Total liabilities | $8.78M | $13.26M | $13.47M | $17.28M | $16.49M | $14.46M | $14.16M | $17.68M |
| Shareholders' equity | $302.03M | $310.70M | $333.30M | $349.00M | $198.37M | $214.38M | $228.49M | $243.03M |
| Shares outstanding | 76.38M | 76.29M | 66.61M | 66.58M | 54.11M | 54.09M | 53.98M | 53.97M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.38M | -$16.04M | -$18.75M | -$16.80M | -$14.19M | -$13.82M | -$15.26M | -$16.76M |
| Capital expenditure | $0 | $108,000 | $8,000 | $159,000 | $90,000 | $65,000 | $0 | $231,000 |
| Free cash flow | -$13.38M | -$16.15M | -$18.76M | -$16.96M | -$14.28M | -$13.88M | -$15.26M | -$16.99M |
| Investing cash flow | $81.13M | $13.78M | -$128.21M | -$1.05M | $18.61M | $13.93M | -$777,000 | $2.26M |
| Financing cash flow | $198,000 | $356,000 | -$312,000 | $168.30M | $64,000 | $301,000 | $0 | $83,000 |
| Depreciation & amortization | $300,000 | $200,000 | $338,000 | $347,000 | $300,000 | $300,000 | $353,000 | $369,000 |
| Stock-based compensation | $2.17M | $3.27M | $3.86M | $3.07M | $3.36M | $2.88M | $3.17M | $2.48M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.